# Boceprevir Treatment in Liver Pre-transplant HCV Patients

> **NCT02160080** · PHASE3 · UNKNOWN · sponsor: **Hu Tsung-Hui** · enrollment: 20 (estimated)

## Conditions studied

- Late Complication From Liver Transplant

## Interventions

- **DRUG:** Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin

## Key facts

- **NCT ID:** NCT02160080
- **Lead sponsor:** Hu Tsung-Hui
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2014-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160080, "Boceprevir Treatment in Liver Pre-transplant HCV Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02160080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*